UPDATE: Evercore ISI Upgrades BioCryst Pharma (BCRX) to Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/18/2026
- US stock futures fall as fading Iran peace prospects drive up oil, yields
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Wall Street indexes slip as oil prices rise, retail results awaited
- Micron rises as White House presses Apple to avoid Chinese memory chips
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Trump threatens to bomb Oman over Iran stance
- H.C. Wainwright Reiterates Buy Rating on Soluna (SLNH)
BioCryst Reports Third Quarter 2022 Financial Results and Upcoming Key Milestones
November 1, 2022 7:00 AM EDT$66.0 million in ORLADEYOÂ Q3 2022 net revenue; on-track to more than double sales in 2022 vs 2021
Underlying patient trends remain strong with nine percent paid patient growth in Q3 2022
Company expands complement pipeline by advancing second oral Factor D inhibitor, BCX10013, into clinical development with goal of once-daily dosing, and adding discovery targets
BCX9930 patient screening underway, data expected from approximately 15 newly-enrolled patients in mid-2023
RESEARCH TRIANGLE PARK, N.C., Nov. 01, 2022 (GLOBE NEWSWIRE) --... More
